| __timestamp | HUTCHMED (China) Limited | Insmed Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 72049000 | 33534999 |
| Thursday, January 1, 2015 | 110777000 | 1982000 |
| Friday, January 1, 2016 | 156328000 | 2438000 |
| Sunday, January 1, 2017 | 175820000 | 2901000 |
| Monday, January 1, 2018 | 143944000 | 2423000 |
| Tuesday, January 1, 2019 | 160152000 | 24212000 |
| Wednesday, January 1, 2020 | 188519000 | 39872000 |
| Friday, January 1, 2021 | 258234000 | 44152000 |
| Saturday, January 1, 2022 | 311103000 | 55126000 |
| Sunday, January 1, 2023 | 384447000 | 65573000 |
Cracking the code
In the competitive landscape of the pharmaceutical industry, cost efficiency is paramount. This chart provides a fascinating comparison between Insmed Incorporated and HUTCHMED (China) Limited over the past decade, from 2014 to 2023.
HUTCHMED has demonstrated a robust growth trajectory, with its cost of revenue increasing by over 400% from 2014 to 2023. This reflects their aggressive expansion and investment in research and development. In contrast, Insmed's cost of revenue has grown by approximately 95% during the same period, indicating a more conservative approach.
The data reveals that HUTCHMED's cost efficiency has consistently outpaced Insmed's, particularly in recent years. By 2023, HUTCHMED's cost of revenue was nearly six times that of Insmed, highlighting their larger scale of operations. This comparison underscores the diverse strategies employed by these companies in navigating the pharmaceutical market.
Pfizer Inc. vs HUTCHMED (China) Limited: Efficiency in Cost of Revenue Explored
Gilead Sciences, Inc. vs Insmed Incorporated: Efficiency in Cost of Revenue Explored
Takeda Pharmaceutical Company Limited vs Insmed Incorporated: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Neurocrine Biosciences, Inc. vs HUTCHMED (China) Limited
Comparing Cost of Revenue Efficiency: Insmed Incorporated vs Jazz Pharmaceuticals plc
Cost of Revenue Comparison: Insmed Incorporated vs Xenon Pharmaceuticals Inc.
Cost of Revenue Comparison: Sarepta Therapeutics, Inc. vs HUTCHMED (China) Limited
Cost of Revenue Trends: Pharming Group N.V. vs HUTCHMED (China) Limited
Cost of Revenue Trends: ACADIA Pharmaceuticals Inc. vs HUTCHMED (China) Limited
Cost of Revenue Comparison: HUTCHMED (China) Limited vs Iovance Biotherapeutics, Inc.
Cost of Revenue Comparison: HUTCHMED (China) Limited vs Wave Life Sciences Ltd.
Comparing Cost of Revenue Efficiency: HUTCHMED (China) Limited vs Travere Therapeutics, Inc.